NL300918I2 - Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride - Google Patents

Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride Download PDF

Info

Publication number
NL300918I2
NL300918I2 NL300918C NL300918C NL300918I2 NL 300918 I2 NL300918 I2 NL 300918I2 NL 300918 C NL300918 C NL 300918C NL 300918 C NL300918 C NL 300918C NL 300918 I2 NL300918 I2 NL 300918I2
Authority
NL
Netherlands
Prior art keywords
pharmaceutically acceptable
acceptable salt
naltrexone
bupropion
hydrochloride
Prior art date
Application number
NL300918C
Other languages
English (en)
Other versions
NL300918I1 (nl
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/en
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of NL300918I1 publication Critical patent/NL300918I1/nl
Publication of NL300918I2 publication Critical patent/NL300918I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL300918C 2003-04-29 2017-12-11 Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride NL300918I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP04760321A EP1617832B1 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss
EP07116330A EP1870096A3 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss

Publications (2)

Publication Number Publication Date
NL300918I1 NL300918I1 (nl) 2017-12-14
NL300918I2 true NL300918I2 (nl) 2018-01-09

Family

ID=38719840

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300918C NL300918I2 (nl) 2003-04-29 2017-12-11 Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride

Country Status (6)

Country Link
EP (1) EP1870096A3 (nl)
BE (1) BE2017C064I2 (nl)
CY (2) CY1119418T1 (nl)
FR (1) FR17C1058I2 (nl)
LU (1) LUC00054I2 (nl)
NL (1) NL300918I2 (nl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111011A2 (en) 2011-02-16 2012-08-23 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
DE69525847T2 (de) * 1994-09-19 2002-09-05 Dupont Pharmaceuticals Co., Wilmington Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
CA2254116C (en) * 1996-05-07 2009-10-20 Ergo Research Corporation Method and composition for the treatment of lipid and glucose metabolism disorders
AU2483599A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1970072A1 (en) * 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
RU2336871C2 (ru) * 2002-05-17 2008-10-27 Тиога Фармасьютиклз, Инк. Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
CY2017041I2 (el) 2018-09-05
BE2017C064I2 (nl) 2023-08-09
FR17C1058I2 (fr) 2019-01-11
CY2017041I1 (el) 2018-09-05
NL300918I1 (nl) 2017-12-14
FR17C1058I1 (nl) 2018-01-12
EP1870096A3 (en) 2011-04-20
LUC00054I1 (nl) 2017-12-13
EP1870096A2 (en) 2007-12-26
LUC00054I2 (nl) 2018-02-21
CY1119418T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
HUS1700052I1 (hu) Opioid antagonistát és bupropiont tartalmazó készítmények súlyvesztés befolyásolására
WO2007089318A3 (en) Compositions and methods for reducing food cravings
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
NL300784I2 (nl) Ketorolac, of het trometamolzout ervan, en fenylefrine, of het hydrochloridezout ervan
TW200605866A (en) Combination of bupropion and a second compound for affecting weight loss
MY130803A (en) New quinuclidine amide derivatives
NO20074441L (no) 1-benzylindol-2-karboksamidderivater
PL401469A1 (pl) Pochodna azabicykliczna, sposób jej wytwarzania, jej zastosowanie w medycynie oraz zawierajaca pochodna kompozycja
DE50309807D1 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2003087094A3 (en) Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
DK1554282T3 (da) Morphinanderivater substitueret i position 14 og deres kvaternære ammoniumsalte, fremstillingsmetode og anvendelse
CA2389650A1 (en) Composition for treatment of constipation and irritable bowel syndrome
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
WO2007014137A3 (en) 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
NL300918I2 (nl) Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride
WO2009032057A3 (en) Method for the selective therapy of disease
HK1089105A1 (en) Pharmaceutical composition of vinflunine for parenteral administration, preparation method thereof and use of same
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
WO2007092157A9 (en) 7-(1h-imidazol-4-yl) methyl) -5,6,7,8-tetrahydroquinoline
WO2005070460A3 (en) Combination therapy with 5-ht1a and 5-ht1b receptor antagonists
AU2002307802A1 (en) Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
JP2004269517A5 (nl)
ATE550335T1 (de) 3,4-dihydro-3-amino-2h-1-benzopyran und - benzothiopyran derivate als dopamine-beta- hydroxylase inhibitoren und verfahren zu ihrer herstellung
IL162822A (en) Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis
PL376403A1 (en) Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists